Ahead of G20 meeting, WHO issues call to arms for R&D push against resistant bacteria

bacteria
WHO says the current antibiotic pipeline is 'practically dry'

The World Health Organization has drawn up a list of the 12 resistant bacteria most problematic to human health—and called on governments and industry to step up efforts to find new medicines to fight them.

The announcement of the list of "priority pathogens" was timed to hit the headlines ahead of the meeting of G20 health experts which started today in Berlin, where the issue of antimicrobial resistance is once again on the agenda.

The aim of the list is to encourage governments to offer incentives for R&D into new antimicrobials by both public and private research groups, says the WHO, and also to find ways to preserve the efficacy of the rapidly dwindling reserve of effective drugs.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Germany's health minister Hermann Gröhe pledged to push for joint action at the G20 meeting, saying: "We have to take joint action today for a healthier tomorrow. Therefore, we will discuss and bring the attention of the G20 to the fight against antimicrobial resistance."

Many of the 12 bacterial families on the list are multidrug resistant (MDR) strains that are a serious threat in clinical units such as hospitals and nursing homes, and in patients who need to be catheterized or have ventilator support.

Many companies in the pharma industry have abandoned antibiotic research to focus on more profitable chronic diseases such as cancer and diabetes, and while some programs such as cross-company consortia have been set up to try to kick-start antimicrobial R&D, these efforts are  simply not sufficient, says the WHO.

"Antibiotic resistance is growing, and we are fast running out of treatment options," says the WHO's assistant director-general for health Systems and innovation Dr Marie-Paule Kieny, who told reporters on a conference call that the antibiotic pipeline is "practically dry."

"If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time."

A 2015 report commissioned by the UK government estimates that antimicrobial resistance could kill more people than cancer by the middle of the century at a cost to society of an eye-watering $100 trillion. The UK has also proposed a scheme that could offer up to $1 billion in prize money for research teams that can come up with effective new drug classes, funded by a surcharge levied on life science companies who decide not to invest in antibiotic R&D.

The WHO's list includes a group of critical pathogens  such as Acinetobacter, Pseudomonas and various Enterobacteriacea—including Klebsiella, Escherichia coli, Serratia, and Proteus species—that have become resistant to a large number of antibiotics including the latest carbapenem and third-generation cephalosporin drugs. 

Two other categories of high- and medium-priority pathogens have been drawn up which include other drug-resistant bacterial diseases such as gonorrhoea and food poisoning caused by Salmonella. The list does not include tuberculosis, as there is already consensus that this is a priority area for R&D, said Kieny.

The ranking of the pathogens is based on how deadly they can be, their tendency to develop resistance mutations, whether infections can lead to long hospital stays and hpw easily they are transmitted.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.